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Summary
Background:  The  vaccine  against  human  papillomavirus  (HPV)  was  created  to  abro-
gate  the  risk  that  the  virus  presents  for  the  development  of  cervical  cancers.  The
prevalence  of  HPV  infection  among  healthy  individuals  is  signiﬁcant  (20%).  We  per-
formed  a  review  of  the  literature  published  in  the  period  from  2008  to  2012  regarding
the  use  of  the  vaccine  against  HPV  speciﬁcally  in  adolescents.
Methods:  The  articles  were  selected  from  a  search  of  the  PubMed  database  with
the  key  words  ‘‘vaccine’’,  ‘‘HPV’’  and  ‘‘adolescent’’.  This  search  identiﬁed  576
articles;  based  on  readings  of  the  titles  and  abstracts,  the  list  of  included  article
was  reduced  to  42.
Results:  We  observed  that  the  majority  of  authors  are  in  favor  of  the  vaccine  for
adolescents  particularly  females.
Conclusion:  Recommending  the  use  of  the  HPV  vaccine  and  other  vaccines  repre-
sents  an  attempt  to  broaden  the  reach  of  these  vaccines  among  both  sexes  of  the
adolescent  population.  Vaccination  is  a  strategy  for  the  prevention  of  pre-cancerous
lesions  in  the  genital  and  oropharyngeal  regions.
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Introduction
World  estimates  have  indicated  that  20%  of  healthy
individuals  are  contaminated  with  the  human
papillomavirus  (HPV)  and  that  this  virus  is  primar-
ily transmitted  through  sexual  contact,  although
direct contact  with  contaminated  objects  can  also
lead to  infection.  HPV  is  related  to  the  development
of approximately  98%  of  the  cases  of  cervical  can-
cers; thus,  infection  with  the  virus  is a  public  health
problem,  and  the  prevention  of  such  infections  is
mandatory  [1—4].
The  prophylactic  vaccine  against  the  HPV  L1  viral
particle  is  an  effective  method  for  the  prevention
of the  infection  of  naïve  women  and  HPV-negative
persons; therefore,  the  Advisory  Committee  on
Immunization  Practices  (ACIP)  of  the  Centers  for
Disease Control  and  Prevention  have  recommended
the universal  administration  of  the  three  doses  of
quadrivalent  or  bivalent  HPV  vaccine  to  girls  of
11—12 years  of  age,  although  the  minimum  recom-
mended  age  varies  with  geographic  region  [2,5,6].
Based  on  a  cost—beneﬁt  analysis,  the  ACIP  rec-
ommended the  administration  of  the  anti-HPV  virus
to 11-  or  12-year-old  girls  for  the  prevention  of  gen-
ital warts,  anal  cancer  and  possibly  cancers  of  the
head and  neck  because  the  vaccine  is  considered  to
be highly  effective  and  provides  protection  against
the four  types  of  HPV  [7,8].
Parents’ interest  vaccinating  their  children  and
the interest  of  adults  (up  to  26  years  of  age)  in  get-
associations  between  some  types  of  cancer  and  HPV
[4,9].
To increase  the  knowledge  of  the  use  of  the
prophylactic HPV  vaccine  in  adolescents,  we  per-
formed  a  review  of  the  published  literature  that
broadly  discussed  this  subject  in  the  period  from
January  2008  to  August  2012.
Methods
Search strategy
The  PubMed  database  was  searched  for  relevant
articles published  in  English  from  2008  to  August
2012.  The  studies  were  grouped  according  to
whether  they  evaluated  the  indications  for  adminis-
tration  of  the  HPV  vaccine  to  adolescents.  A  broad
search strategy  was  pursued  to  capture  the  rele-
vant studies  of  the  HPV  vaccine  and  the  indications
for the  HPV  vaccine  in  adolescents.  The  keywords
‘HPV’, ‘vaccine’  and  ‘adolescent’  were  used.  Data
from longitudinal  studies  were  included,  and  the
references  of  the  retrieved  articles  were  analyzed
to identify  additional  relevant  studies.
Study selection
The  studies  were  selected  based  on  their  titles  and
abstracts,  and  articles  without  available  abstractsting vaccinated  are  directly  related  to  the  relevant
party’s knowledge  of  the  efﬁcacy  of  the  vaccine,
and studies  have  demonstrated  that  the  acceptance
of the  vaccine  is  greater  people  are  aware  of  the
a
t
c
ond full-texts  were  excluded.  Agreement  between
he readers  was  determined  statistically,  and  any
onﬂicts were  resolved  by  discussion  or  the  analysis
f a  third  reader  (GIM).  This  procedure  was  applied
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Table  1  Exclusion  criteria  applied  to  articles
obtained  from  the  search  of  PubMed  for  articles  pub-
lished  in  the  period  from  January  of  2008  to  August  of
2012.
Exclusion  —  subject  or  language  Number  of
articles
Acceptance,  awareness  and
applicability
269
Effectiveness  56
Cost  ×  beneﬁt  of  the  vaccine  39
Barriers  to  implementation  of  the
vaccine
27
Impact  of  the  vaccine  26
Estimate  of  population  immunized  26
General  concepts  about  the  vaccine  17
Opinion  of  persons  vaccinated  15
Perspectives  of  the  vaccine  in
prevention
13
Most  frequent  types  of  HPV  11
Use  of  the  3  doses  (clinical  routine) 7
Simultaneous  use  of  vaccines 6
Other  languages 5
Ethical  and  legal  questions 4
Vaccination  strategies 3
Sexual  behavior  after  vaccination 3
Perspectives  for  the  control  of  cancer 2
Men’s  intention  of  getting  themselves
vaccinated
2
Expression  of  genes  and  production  of
antibodies
2
Free-of-charge  vaccine  distribution  by
clinics
1
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Tndications  for  the  HPV  vaccine  in  adolescents  
t  all  selection  stages.  The  full-text  articles  were
valuated  by  the  readers  using  a  pilot-test  form.
nclusion/exclusion criteria
he  inclusion  criteria  were  the  following:  indica-
ions for  the  administration  of  the  HPV  vaccine  to
hildren  and  adolescents  regardless  of  age  group
nd sex,  and  scientiﬁc  research  projects.  Simple
nd systematic  reviews  were  also  included.
Studies  with  the  following  main  themes  were
xcluded: acceptance,  awareness  and  applicabil-
ty of  the  prophylactic  HPV  vaccine;  efﬁcacy  of  the
accine;  costs  and  beneﬁts  of  the  vaccine;  barri-
rs to  the  implementation  of  the  vaccine;  effect
f the  vaccine  on  society;  estimates  of  the  immu-
ized population;  general  concepts  of  the  vaccine;
pinions  of  vaccinated  persons;  perspectives  on
he vaccine  in  prevention;  most  frequent  types  of
PV; use  of  the  three  doses  in  clinical  routines;
imultaneous  use  of  vaccines,  including  the  HPV
accines;  other  languages;  ethical  and  legal  ques-
ions regarding  the  use  of  the  vaccine;  vaccination
trategies; sexual  behavior  after  vaccination;  per-
pectives for  the  control  of  cancer;  intentions  of
en to  have  themselves  vaccinated;  expression  of
enes and  productions  of  antibodies;  and  free-of-
harge distribution  of  vaccines  by  clinics.  When
ecessary, the  exclusion  criteria  were  reviewed,
nd the  abstracts  were  re-assessed  until  a complete
eﬁnition  of  the  exclusion  criteria  was  determined.
utcomes and variables
he  following  information  was  extracted  from  each
ncluded  study:  year  of  publication;  age-range  of
hose for  whom  the  vaccine  was  indicated;  sex
ndicated to  receive  the  vaccine;  recommendations
egarding HPV  vaccination  of  physicians;  and  the
vailability  of  the  vaccine  to  society.
esults
tudy sample
he  search  detailed  above  resulted  in  the  identiﬁ-
ation  of  576  articles.  After  reading  the  titles  and
bstracts,  534  articles  were  excluded  because  they
ocused on  other  subjects  related  to  the  vaccine
Table  1).  Thus,  our  review  encompassed  a  total  of
nly 42  articles.
p
p
t
aTotal  534
ecommendations of physicians regarding
PV vaccination
f  the  42  included  articles,  ﬁve  addressed  recom-
endations  regarding  the  prophylactic  use  of  the
PV vaccine  (bivalent  or  quadrivalent)  by physi-
ians (Table  2).  Most  of  the  physicians  favored  the
se of  the  vaccine.  However,  many  clinical  opportu-
ities  were  lost.  Possible  reasons  for  these  missed
pportunities  included  the  short  time  of  each  con-
ultation,  forgetfulness  on  the  part  of  doctor,  and
he population’s  absence  of  interest  in  the  HPV  vac-
ine due  to  lack  of  information.
ecommendation regarding HPV vaccination
or females and males
he  42  included  articles  were  in  favor  of  the  pro-
hylactic  use  of  the  HPV  vaccine;  these  articles
articularly emphasized  the  potential  beneﬁts  for
he prevention  of  cervical  cancers.  The  percent-
ges of  articles  that  recommended  the  use  of the
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Table  2  Recommendations  regarding  the  prophylactic  use  of  the  HPV  vaccine  of  each  relevant  article.
Author  and  year  of  publication  Sex  Indication  for  Main  comments
Nadal  and  Nadal  (2008)  [3] Female  11—25  years Vaccination  does  not  dispense  with  the  need  for  period  exams  to  trace
anogenital  cancers,  and  for  the  present  moment  it  is  indicated  for  women  from
11  to  25  years  of  age,  and  is  not  indicated  for  men.Male  Non-indicated
Somasundaram  (2008)  [5] Female  9—26  years  or
more  young
HPV  infections  occur  within  a  few  years  of  the  beginning  of  sexual  activity,  thus
it  is  believed  that  the  prophylactic  HPV  vaccine  should  be  administered  before  9
years  of  age  in  India.  However,  it  is  necessary  for  studies  to  be  conducted  about
the  efﬁcacy  of  the  vaccine  at  this  age.Male  —
Mammas  et  al.  (2009)  [6] Female  9—26  years Understanding  the  natural  history  of  HPV  infection  will  allow  the  application  of
prophylactic  HPV  vaccines  in  the  most  correct  age  groups  for  the  prevention  of
Uterine  cervix  carcinoma  (UCC),  however,  it  is  agreed  that  the  vaccine  is
beneﬁcial  to  the  female  sex  (9—26  years).Male  —
Wright  et  al.  (2009)  [11] Female  11—26  years  and
older  women
In addition  to  the  beneﬁts  of  the  vaccine  to  girls  from  11  to  26  years,
vaccination  can  also  beneﬁt  females  over  the  age  of  26  years  who  have  not
been  previously  exposed  to  HPV  6,  11,  16,  or  18  and  those  who  may  have  new
sexual  partners  in  the  future.Male  —
Garland  et  al.  (2011)  [12] Female  12—13  years Discusses  the  beneﬁts  of  the  vaccination  program  in  girls  (12—13  years)  at
schools  in  Australia,  showing  that  within  a  short  time  after  implementation,  a
reduction  was  observed  in  genital  warts  diagnosed  in  STD  clinics.Male  —
Etter  et  al.  (2012)  [13] Female  9—26  years Although  the  quadrivalent  prophylactic  HPV  vaccine  has  been  approved  since
2006,  and  the  bivalent  vaccine  since  2009,  the  rates  of  uptake  and  completion
of  the  series  of  doses  among  young  women  continue  to  be  low.Male  —
Kahn  et  al.  (2009)  [15] Female  9—26  years,
Priority:  11—12
years
The  study  informs  that  doctors  are  increasingly  more  inclined  to  indicate
prophylactic  HPV  vaccine  for  the  male  sex  as  well,  but  there  is  still  the  need  for
speciﬁc  information  with  respect  to  the  vaccine  for  the  male  sex.
Male  Priority:  11—12
years
Vadaparampil  et  al.  (2011)  [16] Female  11—26  years The  study  suggests  that  innumerable  clinical  opportunities  for  the  application  of
HPV  vaccination  are  lost,  particularly  within  the  ﬁrst  years  of  adolescence  in
the  female  sex  (11—12  years).
Male  Suggest  9—26
years
Weiss  et  al.  (2010)  [17] Female  13—26  years Doctors  who  support  the  use  of  prophylactic  HPV  vaccine  for  the  female  sex  also
believe  in  the  beneﬁts  of  the  use  of  the  vaccine  for  the  male  sex.  However,  they
do  not  agree  that  adoption  of  the  vaccine  for  both  sexes  would  favor
vaccination  coverage,  or  even  change  the  opinion  of  adolescents’  parents  with
regard  to  the  importance  of  the  vaccine.Male  13—26  years
Krupp  et  al.  (2010)  [18] Female  9—26  years The  article  evaluates  the  indication  of  prophylactic  HPV  vaccine  by  doctors  in
India,  and  observes  that  the  minority  indicate  this  with  the  justiﬁcation  that
there  is  no  time  during  the  consultation  to  explain  the  beneﬁts  of  the  vaccine,
since  they  perform  40  attendances  per  day,  which  allows  less  than  ten  minutes
per  consultation.Male  —
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Akinsanya-beysolow  and  Wolfe
(2009)  [19]
Female  9—26  years Reinforces  the  need  for  all  gynecologists  to  explain  the  beneﬁts  and  safety  of
prophylactic  HPV  vaccine  to  the  women  who  consult  them,  because  in  addition
to  being  beneﬁted  by  this  information,  they  may  take  their  children  (present  or
future)  to  receive  the  vaccine,  thus  increasing  this  vaccination  coverage.
Male  Licensure  of  HPV
vaccine  has  been
applied  for
Moscicki  (2008)  [20] Female  9—26  years Emphasizes  the  need  for  creating  vaccines  for  women  who  have  begun  sexual
activity,  since  the  existent  prophylactic  vaccines  are  destined  and  efﬁcient  for
women  who  have  not  yet  engaged  in  sexual  activity.Male  —
Frazer  (2008)  [21] Female  Until  25  years Understands  that  the  prophylactic  HPV  vaccine  is  a  strong  weapon  for  the
prevention  of  uterine  cancer  and  other  lesions  associated  with  HPV.  It  has  been
used  in  many  countries  in  women  up  to  25  years  of  age,  who  have  not  engaged
in  sexual  activity,  an  in  men  based  on  the  safety  and  immunogenicity  of  the
vaccine.
Male  Suggest  until  25
years  too
Castle  et  al.  (2009)  [22] Female  Until  26  years Examining  data  from  7  clinical  centers  in  the  USA,  the  median  age  of  CIN2/3  is
typically  between  25  and  30  years  of  age  in  2007;  if  screen-detected  CIN2/3
develops  on  average  5—10  years  after  the  causal  infection  is  acquired,  HPV
vaccination  will  only  prevent  a  signiﬁcant  proportion  of  CIN2/3  if  it  is  given  to
women  before  the  age  of  26  and  more  so  if  given  to  women  18  and  younger.Male  —
Westra  et  al.  (2011)  [23] Female  12—16  years,  but
can  be  used  until
age  25
Based  on  cost—beneﬁt,  it  is  believed  that  the  preventive  vaccination  program
should  consider  the  target  population  of  the  female  sex  up  to  25  years  of  age.
After  this  age,  the  preventive  program  should  be  of  another  type,  composed  of
routine  exams.Male  —
Harper  and  Paavonen  (2008)  [24] Female  Priority:  until  age
25,  but  indicate
for  older  women
Inform  that  the  safety  and  efﬁcacy  of  prophylactic  HPV  vaccine  are  maintained
when  used  in  older  women  (over  55  years)  who  do  not  present  viral  DNA;
Therefore  they  conﬁrm  that  women  over  the  age  of  26  years  need  to  be
informed  about  this  opportunity  of  being  immunized.Male  9—15  years
Kim  et  al.  (2010)  [25] Female  10—14  years Evaluates  the  safety  and  efﬁcacy  of  prophylactic  HPV  vaccine  (CervarixTM,
GlaxoSmithKline  Biologicals,  Rixensart,  Belgium)  with  adjuvant  AS04  in  Korean
girls  (10—14  years),  which  was  shown  to  be  highly  immunogenic  and  tolerable.Male  —
Bayas  et  al.  (2008)  [26] Female  8—14  years The  optimal  vaccination  strategy  is  vaccination  of  girls  aged  8—14  years.  Other
strategies  should  include  the  uptake  of  adolescent  and  women  not  yet
sexually-active,  as  well  as  the  vaccination  of  sexually-active  women.  The
long-term  HPV  eradication  strategy  will  require  universal  vaccination  of  females
and  males.
Male  Suggest  the
vaccine,  but  not
for  speciﬁc  age
Reiter  et  al.  (2011)  [27] Female  Priority:  11—12
years
Research  conducted  in  the  USA  to  verify  the  number  of  girls  (11—12  years)  who
received  prophylactic  HPV  vaccine,  disclosed  that  few  girls  were  immunized.
The  immunization  strategy  proposed  is  to  carry  out  annual  visits  for  preventive
care  and  administration  of  vaccines  jointly  in  this  age  group.
Male  —
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Table  2  (Continued)
Author  and  year  of  publication Sex  Indication  for Main  comments
Palefsky  (2010)  [28] Female  9—26  years;
Priority:  11—12
years
In  spite  of  ACIP  recommending  the  use  of  the  vaccine  for  the  male  sex  since
2009,  this  recommendation  is  permissive  only  and  not  routinely  implemented.
Taking  into  consideration  the  few  means  of  anal  cancer  prevention,
prophylactic  HPV  vaccine  for  men  is  the  best  long  term  approach  to  prevention
of  the  disease.
Male  9—26  years;
Priority:  11—12
years
Borsatto  et  al.  (2011)  [29] Female  9—26  years In a  review  of  articles,  informs  that  the  target  population  for  prophylactic  HPV
vaccination  are  girls  from  9  to  26  years,  preferably  before  they  become  sexually
active.Male  —
Heideman  et  al.  (2008)  [30] Female  9—18  years By means  of  a  review  of  articles,  inform  that  the  vaccine  could  be  administered
to  girls  of  prepurbertal  age  (9—14  years,  beginning  of  sexual  libido),  girls  from
15—18  years,  who  lost  the  previous  opportunity  of  being  vaccinated,  girls  over
the  age  of  18  years,  who  opted  for  the  vaccine  and  for  adolescents  of  the  male
sex  (10—15  years).Male  10—15  years
Mayer  et  al.  (2012)  [31] Female  Older  age  26 Afﬁrms  that  prophylactic  HPV  vaccine  could  be  safely  administered  in  older
women,  a  group  that  is  not  chosen  by  public  immunization  policies,
nevertheless,  being  a  group  that  may  also  beneﬁt  from  the  use  of  the  vaccine.Male  —
Committee  on  Infectious
Diseases  (2012)  [32]
Female  9—26  years Provides  a  detailed  approach  to  fourteen  items  about  recommendations  for  the
vaccine.  The  article  succinctly  recommends  the  vaccine  for  both  sexes  (9—16
years),  irrespective  of  whether  or  not  sexual  activity  has  begun.  It  also
recommends  it  for  men  over  the  age  of  26  years,  who  maintain  relationships
with  other  men;  and  for  those  with  HIV.  It  does  not  indicate  the  vaccine  for
pregnant  women  and  afﬁrms  that  use  of  the  vaccine  does  not  dispense  with  the
use  of  condoms  and  undergoing  preventive  exams,  such  as  the  Papanicolau  test
(Pap  smear).Male  9—26  years
Panatto  et  al.  (2009)  [33] Female  12—14—16  years They  suggest  vaccination  at  three  ages  (12—14—16  years)  as  a  strategy  so  that
in  a  short  period  of  time  (3—4  years)  the  group  of  women  from  12  to  20  years
could  be  immunized.  The  initial  cost  would  be  compensated  by  the  savings
generated  through  the  reduction  in  lesions  related  to  HPV.Male  —
Rama  et  al.  (2010)  [34] Female  Young
primiparous
women
It  was  observed  that  young  mothers  (15—24  years)  presented  high  prevalence  of
HPV  in  the  cervical  region.  However,  only  13%  of  this  group  of  women  contained
the  high  risk  virus,  characterizing  a  group  eligible  for  receiving  the  vaccine.
Male  —
Torné  et  al.  (2008)  [35] Female  Questions  the  use
HPV  vaccine  for
all
The  article  approaches  the  topic  of  vaccination  as  a  means  that  could  be
applied  to  the  entire  population,  irrespective  of  age,  sexual  habits,  sex  and
systemic  condition.  However,  it  makes  it  clear  that  in  order  to  adopt  this
measure,  it  would  be  necessary  to  await  the  researches  on  the  efﬁcacy  and
safety  of  the  vaccine  for  each  population.
Male  —
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Mogensen  (2009)  [36] Female  9—26  years It emphasizes  that  prophylactic  HPV  vaccination  is  effective  when  used  before
sexual  activity  begins;  however,  there  is  no  evidence  about  the  efﬁcacy  of  the
vaccine  in  women  over  the  ages  of  25—26  years,  which  requires  clinical  studies.Male  —
Reiter  et  al.  (2011)  [37] Female  11—26  years Informs  that  after  one  year  of  the  national  recommendation  for  the  use  of
prophylactic  HPV  vaccine  for  the  male  sex  in  the  USA,  only  2%  of  men  received
the  vaccine.Male  9—26  years
Eggertson  (2012)  [38] Female  — The  National  Advisory  Committee  on  Immunization  says  provincial  governments
should  assess  whether  a  human  papillomavirus  vaccination  program  for  boys
(9—26  years)  is  preferable  to  campaigns  designed  to  increase  female
vaccination  rates.Male  9—26  years
Garnock-Jones  and  Giuliano
(2011)  [39]
Female  — Prophylactic  HPV  vaccination  has  shown  a  high  degree  of  immunogenicity  in  the
male  sex  within  the  age  range  of  9—26  years,  and  is  well  tolerated  and
recommended.Male  9—26  years
Printz  (2009)  [40] Female  9—26  years Emphasizes  the  beneﬁts  of  the  vaccine  for  the  male  sex,  for  the  prevention  of
genital  warts  and  precursor  lesions  of  penile  cancer,  in  addition  to  informing
that  various  doctors  favor  the  use  of  the  vaccine  for  the  male  sex  (9—26  years)
believing  that  the  FDA  will  shortly  support  this  position.Male  9—26  years
Hibbitts  (2010)  [41] Female  9—26  years Supports  the  use  of  the  vaccine  for  men,  afﬁrming  that  in  the  long  term  it
would  be  an  important  factor  in  the  prevention  of  diseases  in  women  as  well.Male  9—26  years
Burki  (2009)  [42] Female  — Points  out  the  importance  of  elucidation  as  regards  the  beneﬁts  of  the  vaccine
for  the  male  sex,  so  that  there  were  be  greater  HPV  vaccine  adherence  by  this
sex.
Male  Support  the
vaccine  for
males.
O’Connor  (2009)  [43] Female  — The use  of  prophylactic  HPV  vaccine  in  the  male  sex,  in  addition  to  being  of
indirect  beneﬁt  to  women,  prevents  important  lesions  related  to  HPV,
irrespective  of  sexual  habits.Male  Until  age  26
Hull  and  Caplan  (2009)  [44] Female  — Reinforces  that  the  vaccination  policy  is  still  focused  on  the  female  sex,
however,  it  should  be  offered  to  and  encouraged  for  both  sexes,  making  it  more
effective  because  of  immunizing  all  possible  carriers  of  the  virus.
Male  Suggest  the
vaccine,  but  not
for  speciﬁc  age
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Table  2  (Continued)
Author  and  year  of  publication  Sex  Indication  for  Main  comments
Paavonen  (2010)  [45] Female  Priority:  Young
adolescents
before  their
sexual  debut
In spite  of  the  target  population  for  receiving  prophylactic  HPV  vaccine  being
girls  before  they  become  sexually  active,  it  is  believed  that  the  inclusion  of  the
male  sex  favors  immunization  of  the  population  in  general.
Male  Suggest  the
vaccine,  but  not
for  speciﬁc  age
Campos-Outcalt  (2012)  [46] Female  — Discloses  that  the  ACIP  has  recommended  prophylactic  vaccination  against  HPV
to  all  men  from  11  to  21  years  and  for  those  men  from  22  to  26  years  of  age,
who  have  sexual  life  with  other  men  or  are  HIV  positive.Male  11—26  years
Smith  et  al.  (2011)  [47] Female  Suggest  the
vaccine,  but  not
for  speciﬁc  age
Evaluates  the  prevalence  of  HPV  in  men,  showing  that  the  male  sex  presents
high  prevalence  of  both  the  high  and  low  risk  viruses,  according  to  the
population  analyzed,  the  need  for  inclusion  of  the  male  sex  in  the  vaccination
programs  is  justiﬁed.Male  Suggest  the
vaccine,  but  not
for  speciﬁc  age
Georgousakis  et  al.  (2012)  [48] Female  9—26  years Although  men  present  fewer  diseases  related  to  HPV  when  compared  with
women,  the  prophylactic  HPV  vaccine  must  be  considered  for  the  male  sex,
since  it  present  beneﬁts  not  only  to  the  men  who  receive  it,  but  to  their
partners  as  well.Male  9—26  years
Kubba  (2008)  [49] Female  Suggest  the
vaccine,  but  not
for  speciﬁc  age
Defends  the  indication  of  prophylactic  HPVB  vaccine  for  adolescents  of  both
sexes,  because  in  addition  to  preventing  lesions,  it  would  also  function  as  a
strategy  to  make  the  immunization  program  successful,  as  there  would  be  no
exclusion  of  adolescents.Male  9—15  years
Gilkey  et  al.  (2012)  [50] Female  11—17  year It was  observed  that  the  number  of  adolescents  of  the  male  sex  who  received
the  vaccine  is  three  times  lower  tan  those  of  the  female  sex.  This  suggests  that
the  prophylactic  HPV  vaccine  should  be  inserted  together  with  the  other
vaccines  in  vaccination  programs.Male  11—17  year
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Table  3  HPV  vaccination  in  a  selection  of  countries.
Countries  Vaccination
system
Target  group
(female)
Vaccine  Period
Australiaa Routine  12—13  years  4-Valent  Since  2009
Catch-up  12—26  years  4-Valent  2007—2009
Denmarka Routine,  via
GPs
12 years  4-Valent  Since  2009
Catch-up,  via
GPs
13—16 years 4-Valent Since  2009
New  Zealanda Routine  13  years  4-Valent  School  year:
2009—2010  and
2010—2011
Catch-up  Girls:  14—20
years
4-Valent  2008—2011
Englanda Routine  12—13  years  2-valent  Since  school  years
2008/2009
Catch-up  13—18  years  2-valent  School  years
2009/2010  and
2010/2011
USAa Routine  Priority:
11—12  years
4-Valent  Since  2007
Catch-up  13—26  years 4-Valent  2008—2011
Netherlanda Routine 12  years 2-Valent  Since  2010
Catch-up  13—17  years 2-Valent  In  2010  only
Francea On
prescription
by  physician
Priority:  14
years
4-Valent  Since  2007
Brazilb Routine  11—13  years  4-Valent  Since  2014
a Ref. [10].
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PV  vaccine  by  females  beginning  at  the  lowest
ges of  8-  to  14-years-old  was  11.9%,  and  50%  of
he articles  recommended  the  use  of  the  HPV  vac-
ine by  females  in  the  highest  age  group  of  9-  to
6-years-old.  Other  age  groups  were  mentioned  by
even articles,  but  these  age  groups  did  not  vary
rom the  age  range  of  8-  to  26-years-old.  Six  articles
entioned  indications  for  the  use  of  the  vaccine
mong males  only,  two  articles  did  not  specify  an
ge range  for  the  use  of  the  vaccine,  and  only  a
ingle article  emphasized  the  indication  for  older
omen  (>26  years).  However,  other  articles  also
uggested  this  possibility  (Table  2).  A  similar  pat-
ern was  observed  regarding  the  recommendations
or males;  9.5%  of  the  articles  recommended  the
PV vaccine  for  boys  aged  9-  to  15-years-old,  and
0.9% of  the  articles  recommend  the  vaccine  for
oys aged  9—26  years  (Table  2).  Seventeen  articles
id not  mention  the  indication  for  the  use  of  the
accine by  males,  six  articles  indicated  the  vaccine
ithout  specifying  an  age  group,  and  only  a  single
rticle  indicated  another  age  group  (11—17  years).
ne article  adopted  a  position  against  the  prophy-
actic  use  of  the  HPV  vaccine  by  males  (Table  2).
D
T
tvailability of the vaccine to society
any  countries  in  which  the  authorities  are  con-
inced of  the  safety  and  efﬁcacy  of  the  prophylactic
se of  the  HPV  vaccine  are  ﬁnancing  the  adminis-
ration  of  the  vaccine  to  adolescents  because  these
uthorities  understand  that  vaccination  represents
 preventive  strategy  with  a  favorable  cost—beneﬁt
atio. Table  3  presents  important  data  regarding  the
accination policies  of  several  countries,  including
he adopted  vaccination  system,  the  age  of  the  tar-
et population,  the  type  of  vaccine  applied  (i.e.,
ivalent  or  quadrivalent)  and  the  year  in  which  the
accination  program  began.  We  observed  that  75%
6/8) of  the  countries  adopted  programs  of  routine
accination  of  12-year-old  female  adolescents,  and
nly two  countries  opted  for  the  bivalent  rather
han the  quadrivalent  vaccination  (Table  3).iscussion
he  main  target  populations  of  national  immuniza-
ion programs  are  adolescent  girls  regardless  of
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whether  they  have  initiated  sexual  activity;  how-
ever, it  is  probable  that  many  adult,  sexually  active
women  wish  to  receive  the  vaccine  for  their  individ-
ual beneﬁt.  Therefore,  Wright  et  al.  [11]  considered
the use  of  the  vaccines  to  be  acceptable  in  mod-
ern clinical  practice  because  these  vaccines  are
immunogenic  and  safe  for  use  in  sexually  active
women. In  Australia,  young  adolescents  (10—17
years) are  vaccinated  through  a  project  that  is  car-
ried out  in  schools,  and  Australia  is  the  ﬁrst  country
to provide  the  vaccine  via  a  public  health  program
[12,13].  Many  countries,  including  Brazil,  offer  pro-
phylactic HPV  vaccine  to  females,  primarily  those
12- to  13-years-old.  In  Brazil,  a  vaccination  program
for 11-  to  13-year-old  girls  provided  through  the  Sis-
tema Único  de  Saúde  (SUS)  national  health  system
was approved,  and  the  campaign  was  scheduled  to
begin in  March  2014  [10,14].
Studies have  evaluated  the  recommendation
that the  vaccine  be  administered  by  physicians
(i.e., general  clinicians,  pediatricians  and  gyne-
cologists),  and  these  studies  have  reported  that  a
minority of  these  physicians  provided  their  patients
with guidance.  This  ﬁnding  indicates  that  innumer-
able  clinical  opportunities  for  vaccinations  against
HPV have  been  lost  [15,16]. In  the  USA,  despite
the existence  of  national  guidelines  recommen-
ding the  vaccine  for  11-  to  26-year-old  women,
the proportions  of  physicians  who  indicate  to  their
patients  that  they  always  recommend  the  vaccine
ranges from  25.8%  and  74.5%  depending  on  the
age range  of  the  patients  and  the  specialties  of
the physicians  [17]. However,  in  another  study  that
analyzed  the  indications  for  the  use  of  the  vac-
cine in  men,  variation  in  the  recommendations  for
the use  of  the  vaccine  also  occurred  with  age;
the vaccine  was  indicated  for  11-  to  12-  (63.9%),
13- to  18-  (93.4%)  and  19-  to  26-  (92.7%)  year-old
males. Therefore,  this  medical  recommendation  is
an important  and  consistent  factor  for  use  of  the
vaccine  [16,17].
In  India,  it  has  been  observed  that  doctors  do  not
doubt the  efﬁcacy  of  the  vaccine;  therefore,  the
lack of  time  during  consultations  has  been  found  to
be the  main  justiﬁcation  for  the  non-indication  of
the vaccine.  These  doctors  were  required  to  pri-
oritize  other  subjects  during  consultations  or  to
discuss mandatory  vaccines  [18].  The  author  of  the
study explained  that  it  is necessary  for  gynecolo-
gists and  obstetricians  to  explain  the  importance
of the  vaccine  to  women,  not  only  to  encour-
age them  to  be  vaccinated  but  also  so  that  those
women  will  have  their  future  children  vaccinated
because women  generally  care  for  the  health  of
their families  [19].  Doctors  believe  that  invest-
ments in  campaigns  about  the  importance  of  the
t
[
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PV  vaccine  would  make  patients  themselves  seek
accination  [18].
A large  portion  of  the  authors  indicated  vaccina-
ion for  women  from  11  to  26  years  of  age  who  are
ot yet  sexually  active;  i.e.,  those  without  previous
xposure  to  the  virus  [3,6,20—28].  However,  Bor-
atto [29]  indicated  vaccination  for  all  women  aged
—26 years  regardless  of  sexual  activity,  and  others
uthors,  such  as  Heideman  et  al.  [30],  included  indi-
ations for  older  women  based  on  the  perspective
hat the  vaccine  is  a  safe  and  effective  invest-
ent [24,31]. The  quadrivalent  vaccine  (HPV4;
ardasil;  Merck  &  Co,  Inc.,  Whitehouse  Station,
J) is  contraindicated  for  persons  with  histories  of
mmediate  hypersensitivity  to  yeast  and  pregnant
omen [32].
Despite  the  concern  regarding  the  vaccination
f girls  who  have  not  initiated  sexual  activity,  i.e.,
requently  children  (9  years),  authors  believe  that
he administration  of  the  vaccine  at  an  early  age
ight reduce  the  immunity  offered  by  the  vaccine
ecause  it  is  used  well  before  the  phase  of  high
evels of  exposure  to  HPV  infection  [30],  which
requently occurs  among  14-  to  16-year-old  girls;
hus, the  vaccine  is  needed  for  this  latter  age
roup [33]. Another  target  population  for  vaccina-
ion is  young  primiparous  women  (15—24  years  of
ge) among  whom  the  prevalence  of  HPV  in  the
ervical  region  is  high.  In  one  study  group,  58.5%
176/301)  of  such  women  were  HPV-positive,  and
3% carried  oncogenic  types  of  HPV  (i.e.,  HPV-16
nd HPV-18).  This  group  of  women  is  considered
o be  at  high  risk  for  the  development  of  cervi-
al cancer;  therefore,  vaccination  is proposed  to
hese women  during  the  post-natal  consultation
o prevent  infections  with  the  oncogenic  types  of
PV [34].
The vaccine  might  prevent  approximately  70%
f the  cases  of  cancer  of  the  uterus  and  is thus
onsidered a means  of  eliminating  one  of  the  most
orrying  female  diseases  and  a  disease  with  a  high
ncidence  in  India  [5,21]. Thus,  some  authors  have
een encouraged  to  develop  new  research  programs
egarding the  creation  of  effective  vaccines  for
omen  who  have  initiated  sexual  activity,  those
ho are  infected  by  the  virus,  and  for  immuno-
uppressed patients  [20,35]. Others  believe  that
nfection  prevention  programs  for  older  women
ust be  of  a  different  type  because  vaccination
rograms are  no  longer  economically  feasible  for
hese women  because  the  efﬁcacies  of  such  pro-
rams have  not  been  proven  in  clinical  trials,  and
he virus  is  not  highly  prevalent  in  this  age  group
23,36].
Regarding  males,  although  Nadal  and  Nadal  [3]
oes  not  agree  about  the  beneﬁts  of  the  vaccine  for
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[ndications  for  the  HPV  vaccine  in  adolescents  
ales,  in  the  USA,  a  recommendation  for  the  pro-
hylactic  use  of  the  HPV  vaccine  by  men  between
he ages  of  9  and  26  years  was  issued,  but  one  year
fter this  recommendation  was  issued,  the  rate  of
accination  among  males  of  this  age  group  was
inimal (2%).  This  ﬁnding  indicates  the  need  for
trategies  to  increase  the  use  of  the  vaccine  by  this
opulation;  such  strategies  should  include  explana-
ions about  the  disease,  how  it  also  affects  men,
ow it  can  be  prevented  and  how  the  risk  to  sexual
artners can  be  minimized  [37—45].  Currently,  the
CIP states  that  the  HPV  vaccine  must  be  adminis-
ered to  men  between  from  11-  to  21-years-old  and
o men  from  22-  to  26-years-old  who  maintain  sex-
al relationships  with  other  men  or  are  HIV-positive
46].
HPV-16  is  the  most  frequent  type  of  infection
n men  irrespective  of  age;  therefore  further  stud-
es are  needed  to  determine  the  best  age  group
or the  vaccination  of  the  males,  although  some
ave already  stated  that  the  appropriate  age  is
he beginning  of  adolescence  (10—15  years  of  age)
30,47].  In  Australia,  despite  the  belief  that  the
accination  of  men  would  beneﬁt  to  the  population,
here is still  no  program  that  ﬁnances  the  vaccina-
ion of  men,  and  the  author  of  the  relevant  study
elieves that  it  is  not  possible  to  vaccinate  the
ajority  of  the  male  population  without  ﬁnancing
rom the  government  [48].
Thus, recommendations  in  favor  of  the  prophy-
actic uses  of  the  HPV  vaccine  and  other  vaccines
ave made  these  vaccines  more  accessible  to  both
exes of  the  adolescent  populations,  and  such
ecommendations  represent  a  strategy  for  the  pre-
ention  of  pre-cancerous  lesions  in  the  genital  and
ropharyngeal  regions  [49,50].
onclusion
espite  the  small  divergences  regarding  the  best
ndications  for  the  use  of  the  HPV  vaccine  accord-
ng to  age,  sex  and  sexual  habits,  all  of  the  reviewed
cientiﬁc  articles  maintained  that  the  vaccine  is  an
ffective means  of  prevention  even  when  its  use
s restricted  to  a  speciﬁc  section  of  the  population.
he continuous  study  of  articles  is  extremely  impor-
ant for  our  understanding  of  the  properties  of  the
accine  and  the  beneﬁts  it  provides  to  certain  pop-
lation  groups,  particularly  those  groups  that  are
ot targets  for  this  immunization.unding
o  funding  sources.
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